Epilepsy Drugs Market Report and Forecast 2024-2032

Epilepsy Drugs Market Size

The epilepsy drugs market was valued at USD 8193.5 million in 2023, driven by the rising prevalence of epilepsy and neurological disorders across the 8 major markets. The market is expected to grow at a CAGR of 4.40% during the forecast period of 2024-2032, with the values likely to attain USD 12025.78 million by 2032.

Epilepsy Drugs Market Outlook

• In October 2023 a study revealed XEN1101's efficacy in reducing seizures by over 50%, offering a swift, safe, and effective treatment for focal epilepsy, potentially reshaping the landscape of epilepsy drug therapy globally.

• In January 2024, Eisai Co., Ltd. for Fycompa® injection was approved in Japan, offering a solution for temporary inability to administer oral medication, ensuring uninterrupted epilepsy treatment.

• The epilepsy drugs market is expected to be driven by technological advancements in diagnostic tools and treatment modalities, such as neuroimaging techniques and neuromodulation devices contributing to the market expansion.

Epilepsy Drugs Market Overview

Epilepsy is a neurological disorder characterised by recurrent seizures, affecting millions globally. The epilepsy drugs market is driven by the increasing prevalence of epilepsy, due to which the need for the development of innovative antiepileptic drugs (AEDs) by pharmaceutical companies has heightened. The market is fuelled by the escalating advancements in personalised medicine and diagnostic technologies. The rising efforts to increase awareness among people about the available treatments are also contributing to the market growth. With expanding healthcare infrastructure in developing regions, the epilepsy drugs market is poised for substantial growth.

Epilepsy Drugs Market Growth Factors

Regulatory Approvals Marking Significant Milestones in Epilepsy Treatment

In January 2024, the Japanese Ministry of Health, Labour and Welfare approved Fycompa® (perampanel), the injection form of an antiepileptic drug (AED) in Japan. The drug is an internally developed product of Eisai Co., Ltd and has been approved particularly as an alternative during situations when oral administration is temporarily impossible. Fycompa, an innovative AED discovered at Eisai’s Tsukuba Research Laboratories. It acts as a highly selective, noncompetitive AMPA receptor antagonist, aiming to mitigate neuronal hyper-excitation associated with seizures by modulating glutamate activity.

This injection offers continuity in epilepsy patients by addressing concerns of interrupted treatment during situations like surgeries. Being the sole AMPA receptor antagonist-based AED, this expansion of Fycompa’s administration route facilitates patients who are unable to use oral medication temporarily. The major focus of Eisai Co., Ltd has always been neurology, and epilepsy in particular. This development aligns with the company’s vision to enhance the quality of life for epilepsy patients. Such innovative drug developments and expanded treatment options are poised to drive the market growth, meeting the diverse needs of patients worldwide and potentially driving market expansion in the forecast period.

Surge in Drug Development Initiatives to Meet Rising the Epilepsy Drugs Market Demand

In October 2023, a groundbreaking study discovered the efficacy of an investigational medication, XEN1101, in significantly reducing seizure frequency. The medication demonstrated a reduction of more than 50 percent in some patients and even eliminated seizures overall in some patients, which is a significant advancement in epilepsy treatment. The positive findings from the phase 2b clinical trial conducted at NYU Grossman School of Medicine underscore XEN1101's potential as a swift, safe, and effective adjunctive therapy for focal epilepsy.

As XEN1101 offers a novel mechanism of action as a potassium-channel opener, it represents a significant breakthrough in epilepsy drug development. These promising results are poised to drive substantial growth in the market as patients and healthcare providers increasingly embrace this innovative treatment option. Such advancements also contribute to expanding pharmaceutical companies' market opportunities and fostering advancements in epilepsy care worldwide, fuelling the market growth.

Epilepsy Drugs Market Trends

Epilepsy Drugs Market Segmentation 

Market Breakup by Seizure Type
 

• Focal Seizures

• Generalized Seizures

• Non-epileptic Seizures

• Others

Market Breakup by Drug Generation

• First Generation Drugs

• Second Generation Drugs

• Third Generation Drugs

Market Breakup by Age Group

• Pediatric

• Geriatric

• Adult

Market Breakup by Route of Administration

• Oral

• Nasal

• Injectable

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Drug Stores and Retail Pharmacies

• Online Providers

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Epilepsy Drugs Market Share

Focal Seizures Lead Seizure Type Segmentation

Seizure type segmentation includes focal seizures, generalized seizures, non-epileptic seizures, and others. Focal seizures lead the market segment due to their prevalence and distinct characteristics. Focal seizures require targeted treatment approaches, driving pharmaceutical companies to develop specialised medications, tailored to address the unique needs of patients experiencing focal epilepsy.

First Generation Dominates the Drug Generation Segmentation

Market share based on drug generation includes first-generation drugs, second-generation drugs, and third-generation drugs. Out of these, first-generation drugs dominate the drug generation segmentation in the global market. This can be attributed to its established efficacy, familiarity among physicians, and lower cost compared to newer generations.

Oral Route of Administration Most Preferred

Market segmentation based on the route of administration includes oral, nasal, injectable, and others.  The oral route of administration is most preferred in the global epilepsy drugs market due to its convenience, ease of use, and high patient acceptance. Oral medications offer flexible dosing regimens while providing efficient systemic drug delivery simultaneously, contributing to better seizure management and patient compliance.

Epilepsy Drugs Market Analysis by Region

Based on the regional analysis, the market covers United States, EU-4 (Germany, France, Italy, Spain)and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. The United States leads the epilepsy drugs market due to factors such as an increasing prevalence of the condition, presence of advanced healthcare infrastructure, robust research and development activities, and significant investments in innovative drug therapies. Additionally, favorable regulatory policies and strong market competition contribute to the region's dominance in the market.

Further, Japan and India are witnessing steady growth due to rising prevalence, improving healthcare infrastructure, increasing awareness, and better access to treatment options. The region is poised to witness a significant growth in the forecast period.

Leading Players in the Epilepsy Drugs Market

The key features of the market report include patent analysis, grants analysis, clinical trial analysis, and latest strategic initiatives by the leading players. The major companies in the market are as follows:

GlaxoSmithKline Plc

GlaxoSmithKline Plc (GSK) was established in 2000 and is currently headquartered in Brentford, London. It is a prominent pharmaceutical company with a significant market presence. Some of the well-known epilepsy drugs include Lamictal (Lamotrigine), Epanutin (Phenytoin) and Trobalt (Retigabine) among others.

Eisai Co., Ltd.

It is a leading pharmaceutical company based out of Japan. This company is dedicated to develop and discover several effective drugs that address the different needs of patients.

Novartis AG

It is a Swiss multinational pharmaceutical company based out of Switzerland and known for its elaborate portfolio of epilepsy drugs. Tegretol (Carbamazepine), Trileptal (Oxcarbazepine) and Sabril (Vigabatrin) are some of the examples.

Other companies in the market include UCB Pharma S.A, Sanofi, S K Biopharmaceuticals, Novel Laboratories Inc., Pfizer Inc., Neurelis, Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Sumitomo Pharma, Jazz Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd. and Alkem Laboratories Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Epilepsy Drugs Market Report

• What was the epilepsy drugs market value in 2023?  
• What is the epilepsy drugs market forecast outlook for 2024-2032?  
• What are the major factors aiding the market demand?  
• What are the major market trends? 
• What is the market segmentation based on the seizure type?
• What is the market breakup by drug generation?
• How is the market segmented based on the route of administration?
• What are segments based on distribution channels?
• Which age group does this drug serve?
• What are the major markets according to the EMR report? 
• Who are the key players in the epilepsy drugs market?
• How will the market landscape evolve in the upcoming years? 
• What are the major drivers, opportunities, and restraints in the market? 
• What will be the effect of each driver, challenge, and opportunity on the market? 
• Which country is poised to lead the market share in the forecast period? 
• Which segment has the highest impact on the market size? 
• What is the patent landscape of the market?
• What drugs are currently under clinical trials?
• How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?